Status:
TERMINATED
Pharmacogenetic Prediction of Metoprolol Effectiveness
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Hypertension
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clini...
Eligibility Criteria
Inclusion
- Subjects between age \>30 years and \< 80 years
- Subjects have diagnosis of uncontrolled essential hypertension.
Exclusion
- end stage liver disease,
- end stage renal disease,
- pregnant females,
- American Society of Anesthesiologists (ASA) classification of \>3,
- wards of the state, prisoners,
- decisionally challenged,
- HR\<60 bpm,
- AV block\>240 msec,
- active reactive airway disease,
- illicit drug abuse in the preceding 30 days,
- hypersensitivity to metoprolol or its derivatives
- severe peripheral arterial circulatory disorders.
- Subjects will have a screening physical exam performed by Dr. Monte prior to enrollment in the study.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 23 2017
Estimated Enrollment :
462 Patients enrolled
Trial Details
Trial ID
NCT02293096
Start Date
September 1 2014
End Date
August 23 2017
Last Update
September 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver; Emergency Department
Aurora, Colorado, United States, 80045